Studies with desogestrel for fertility regulation
Over the past 20 years Organon have been involved in developing a new series of progestogens characterized by the absence of an oxygen at position 3 of the steroid skeleton. Following lynestrenol, the most promising compound in early trials was desogestrel, a 13-ethyl-11-methylene-3-desoxy compound, which is a more specific progestogen than both norethisterone and levonorgestrel1. Receptor binding studies have demonstrated a lower affinity of the main metabolite of desogestrel for androgen receptors than levonorgestrel1.
KeywordsOral Contraceptive Serum Lipoprotein Oral Contraception Serum High Density Lipoprotein Cholesterol Breakthrough Bleeding
Unable to display preview. Download preview PDF.
- 3.Samsioe, G. (1982). Comparative effects of the oral contraceptive combinations 0.0150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers. Contraception, 25, 487PubMedCrossRefGoogle Scholar
- 7.Burstein, M., Scholnik, H. R. and Morfin, R. (1978). Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid. Res., 11, 583Google Scholar
- 8.Winer, B. J. (1971). Statistical Principles in Experimental Design. ( New York: McGraw Hill )Google Scholar
- 13.el Makzangy, M. N., Wynn, V. and Lawrence, D. M. (1979). Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin. Endocrinol., 10, 39Google Scholar